inmates is reported to be high, little is known about anti-HIV treatment patterns in correctional institutions. The present study assessed antiretroviral prescribing patterns for 2360 Texas Department of Criminal Justice (TDCJ) inmates infected with HIV. In 1998, 66.8% of all TDCJ inmates infected with HIV who had CD4 lymphocyte counts !500 cells/mm 3 were treated with highly active antiretroviral therapy (HAART). However, no substantial differences in the use of HAART were exhibited according to the sociodemographic factors under study. While the majority of inmates receiving HAART in 1998 were prescribed a combination of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 protease inhibitor, 11.2% were prescribed a combination of 2 NRTIs and 1 non-NRTI. In view of the elevated rate of HIV infection in correctional settings, it will be important to continue to document the pharmacotherapy patterns among prison inmates, both during and following incarceration.
in the general population [15] . Despite this, information on the treatment patterns for inmates infected with HIV in the United States prison system is scarce. The purpose of the present study, therefore, was to assess antiretroviral prescribing patterns for inmates infected with HIV.
Patients and Methods
The cohort under study consisted of 2360 prison inmates who were incarcerated in the Texas Department of Criminal Justice (TDCJ) system for any duration during the period of 1 January 1998 through 31 December 1999 and who were infected with HIV. Texas houses one of the largest prison populations in the United States and, together with California, houses almost one-third of all US prison inmates [16] . All TDCJ inmates are required to have medical examinations at the time of incarceration. This evaluation consists of a detailed medical history, a comprehensive physical examination, and a number of diagnostic procedures. For the medical history, information is sought about HIV risk factors such as history of injection drug use, occurrence of sexually transmitted diseases, and history of homosexual/bisexual activity. Patients who report having any of these risk factors are counseled about their risk for HIV infection and are offered HIV serological screening. In addition, patients who report having previously tested positive for HIV infection or who have symptoms of HIV infection (at any point during the incarceration) are also offered screening. Testing for HIV is not mandatory for TDCJ inmates, however.
HIV serological screening consists of ELISAs with confirmatory tests (immunofluorescent assay or Western immunoblotting). All inmates who test positive for HIV infection are placed under the Downloaded from https://academic.oup.com/cid/article-abstract/31/6/1476/372088 by guest on 06 December 2018 care of university-appointed, experienced AIDS practitioners, including physicians, physician assistants, and nurses. Medication prescription data are maintained on all inmates who are prescribed medication during their incarceration. Inmates at all TDCJ facilities are required to obtain each dose of their prescribed medication at a designated "pill window." Each dose is recorded and entered into a computerized database. The present study examined use of 3 classes of antiretroviral medication: nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). Other classes of antiretrovirals represented !1% of the prescribed treatment in the study cohort and therefore were not included in the present study. HAART was defined as 2 NRTIs prescribed with either a PI or an NNRTI. Specific pharmaceutical information for inmates who were enrolled in clinical trials of HAART was not available. Therefore, these patients were classified as having been prescribed HAART but were not included in either of the 2 specific HAART subclassification tabulations.
Study variables. All clinical, pharmacological, and sociodemographic data used in the present investigation were obtained from a system-wide medical information system. This system is routinely updated to include each inmate's current health status. Inmates who were not identified as white, black, or Hispanic accounted for !1% of the study population and therefore were included in the white category. For the majority of inmate patients infected with HIV, CD4 lymphocyte counts were recorded at multiple times during treatment. For the present study, the CD4 lymphocyte count was estimated on the basis of the reading obtained closest to the midpoint of the study period (1 July 1998). A small number of inmates who did not have a CD4 lymphocyte count recorded within 3 months of this date were classified as having a missing CD4 lymphocyte count.
Patients in the early stages of HIV infection were less likely to have been treated by the university clinical HIV staff and therefore were less likely to have been enrolled in the university-based study that received approval from the institutional review board to record CD4 lymphocyte count data and other clinical information. Consequently, patients whose CD4 lymphocyte counts were missing represented a comparatively healthy subgroup of patients infected with HIV.
The outcome variable (the prescribed antiretroviral regimen) was defined as 1 of 3 categories: HAART, NRTI only, or no antiretroviral therapy. The HAART outcome consisted of 3 categories: all HAART, NRTI with PI, and NRTI with NNRTI. Patients could be included in у1 of the outcome categories if their therapy changed during the course of the study period. For example, if a patient was prescribed NRTI-only therapy from February 1998 through April 1998 but was switched to NRTI-with-PI therapy from May through December 1998, then that patient would be counted in both categories. However, only 94 (4%) patients of the study population infected with HIV were prescribed у1 antiretroviral regimen during the study period.
Statistical analysis. For the bivariate statistical analyses used in the present study, the percentages of inmates prescribed specific classes and combinations of antiretroviral drugs were compared according to CD4 lymphocyte count and sociodemographic factors on the basis of prevalence and associated 95% CIs for each subgroup under study. Subgroups with CIs that did not overlap were considered to have statistically significant differences from one another. Logistic regression was then used to assess the association of the explanatory variables of CD4 lymphocyte count, sex, age, and race with each of the dichotomous response variables.
Results
The vast majority of TDCJ inmates were male and aged 30-49 years (table 1) . Of the 139,573 members of the cohort study, 40,040 (28.7%) were white inmates and 36,676 (26.3%) were Hispanic inmates, and blacks accounted for 62,858 (45%) of the inmates. Blacks and inmates aged 30-49 years were substantially overrepresented among inmates infected with HIV. Hispanics, as well as inmates in the youngest and oldest age groups, were substantially underrepresented in the subcohort infected with HIV.
One thousand one hundred and fifty-two (48.8%) of the 2360 TDCJ inmates infected with HIV were prescribed HAART during 1998 (table 2) . Black, male, and older inmates accounted for the highest proportions of patients on HAART, although none of these associations reached statistical significance. Inmates with CD4 lymphocyte counts !500 cells/mm 3 accounted for a substantially higher percentage of HAART recipients (796 [66.8%] of 1191 patients) than did inmates with CD4 lymphocyte counts у500 cells/mm 3 (169 [38%] of 445 patients). Moreover, the proportion of inmates receiving HAART increased steadily with each drop in the CD4 lymphocyte count category, with the exception of a slight decrease in the lowest CD4 lymphocyte count category. Assessment of the 95% CIs indicated that patients with CD4 lymphocyte counts у500 cells/mm 3 and those with missing CD4 information accounted for substantially lower proportions of inmates receiving HAART than did any of the other subgroups. Of the 48.8% prescribed HAART, 43.2% received NRTIwith-PI therapy, and 11.2% received NRTI-and-NNRTI therapy (table 2) . These 2 subgroups are not mutually exclusive. That is, a patient may have been switched from one course of HAART to another within the calendar period of 1998 and thereby be classified in both categories. Once again, among inmates with CD4 lymphocyte counts !500 cells/mm 3 , there was a substantially higher rate of HAART than among inmates with CD4 lymphocyte counts 1500 cells/mm 3 . Moreover, in both of the HAART subgroups, with each decrease in the CD4 lymphocyte count category there was a stepwise increase in the proportion of patients receiving the prescribed regimen of interest.
Overall, 1515 (64.2%) of the 2360 inmates infected with HIV were prescribed NRTI-only therapy in 1998 (table 2) . Inclusion in the NRTI-only category did not preclude having been prescribed HAART in 1998. In fact, 953 (44.9%) of the 2123 male inmates infected with HIV were prescribed both HAART and NRTI-only therapy in 1998. It is interesting that the proportion of inmates prescribed NRTI-only therapy increased in a stepwise fashion with each drop in the CD4 lymphocyte count category. Assessment of the 95% CIs indicated that the prevalence of NRTI-only therapy was substantially reduced among inmates with CD4 cell counts у500 cells/mm 3 and among those whose counts were missing. No other statistically significant differences, however, were noted among the other CD4 lymphocyte count subgroups.
Overall, 739 (31.3%) of the 2360 inmates infected with HIV were prescribed no antiretroviral therapy during 1998 (table 2) . Among female, Hispanic, and young inmates (aged 18-29 years), percentages of those who received no antiretroviral therapy were elevated. None of these associations, however, were statistically significant. As expected, this percentage decreased in a stepwise fashion according to CD4 lymphocyte count. The percentage of patients receiving no antiretroviral therapy was substantially higher among inmates with CD4 lymphocyte counts у500 cells/mm 3 or whose counts were missing than among inmates with CD4 lymphocyte counts !500 cells/mm 3 . Logistic regression models were used to examine the influence of the study factors on the dichotomous response variable: HAART prescription during 1998 (table 3) . Of the variables included in the model, only CD4 lymphocyte count was predictive of prescription of HAART. More specifically, relative to the reference category (patients with CD4 lymphocyte counts у500 cells/mm 3 ), patients in the other 4 CD4 lymphocyte count categories (0-99, 100-199, 200-299, and 300-499 cells/mm 3 ) all had a significantly greater likelihood of being prescribed HAART. Alternatively, inmates whose CD4 lymphocyte counts were missing had a significantly lower likelihood of receiving HAART.
The association of the study factors with the 2 specific types of HAART under study, NRTI with PI and NRTI with NNRTI, showed that the CD4 lymphocyte count was, once again, predictive of the outcome (the prescribed antiretroviral regimen) of NRTI with PI. However, this factor was not predictive of prescription of NRTI-and-NNRTI therapy, probably as a result of the small sample size on which this model was calculated. None of the sociodemographic factors under study were predictive of either of the outcomes.
Of the study factors examined in the model assessing the Downloaded from https://academic.oup.com/cid/article-abstract/31/6/1476/372088 by guest on 06 December 2018 outcome (prescription) of NRTI-only therapy, only CD4 lymphocyte count was predictive. In comparison to the reference group, each of the other CD4 lymphocyte count categories carried an increased likelihood of prescription of NRTI therapy at some point in 1998. In fact, the risk ratios increased in a monotonic fashion with each drop in CD4 lymphocyte count. Finally, none of the sociodemographic variables under study were predictive of the outcome in which no antiretroviral regimen was prescribed. However, examination of CD4 lymphocyte count showed that relative to the reference category (patients with CD4 lymphocyte counts у500 cells/mm ) were all significantly less likely to have no antiretroviral medication prescribed, whereas patients whose CD4 lymphocyte counts were missing were significantly more likely to have no antiretrovirals prescribed.
Discussion
Despite the reportedly high rates of HIV infection in the United States prison system [1] [2] [3] , little research has been conducted on the delivery of pharmacotherapy to prison inmates infected with HIV. In view of the clear benefit of newer antiretroviral regimens for patients infected with HIV, it is particularly important to understand prescribing patterns for this population. A number of such studies have been conducted in nonincarcerated populations infected with HIV [8, 17, 18] . However, no such information has been published on prison populations. The purpose of the present study, therefore, was to describe antiretroviral prescribing patterns in the TDCJ, one of the 3 largest prison systems in the United States [16] .
A number of recent studies have shown that HAART can profoundly suppress viral replication in patients infected with HIV [7] [8] [9] [10] [11] [12] [13] [14] . Consistent with these findings, HAART has also been reported to reduce both mortality and morbidity among patients testing positive for HIV [17] . As a result of such findings, the US Department of Health and Human Services (DHHS) [19] currently recommends that HAART be given to all patients with CD4 lymphocyte counts !500 cells/mm 3 . The present study shows that among TDCJ inmates infected with HIV who had CD4 lymphocyte counts !500 cells/mm 3 , 796 (66.8%) of 1191 patients were prescribed HAART in 1998. As expected, this percentage generally increased as CD4 cell count dropped, indicating that inmates with more advanced HIV disease were more likely to have received HAART. The proportion of TDCJ inmates infected with HIV who had CD4 lymphocyte counts !500 cells/mm 3 and were prescribed HAART was substantially lower than proportions revealed in previous studies of nonincarcerated populations [8, 17, 18] . For example, in their survey of the use of HIV services in the United States, Shapiro et al. [18] reported that among patients infected with HIV who had CD4 lymphocyte counts !500 cells/mm 3 , 59% received HAART in 1996 and 85% received HAART in 1997.
Likewise, in their study of 1255 patients infected with HIV in the United States with CD4 cell counts !100 cells/mm 3 , Palella et al. [17] noted that in 1997 180% of these patients received HAART. In their study of HIV pharmacotherapy regimens in the United States, Brosgart et al. [8] reported the following percentages of patient subgroups were prescribed HAART in 1996: 4%-37% of those with CD4 lymphocyte counts of 200-500 cells/mm 3 ; 35%-78% of those with counts of 50-200 cells/mm 3 ; and 46%-86% of those with counts !50 cells/mm 3 . Of course, in comparing these investigations with the current study, it is important to consider the variation in calendar period of observation, CD4 lymphocyte count cutoff points, and sociodemographic composition of the respective study samples.
In each of the reviewed studies [8, 17, 18] and the present investigation, substantial numbers of patients did not receive treatment that was consistent with the DHHS guidelines [19] . In fact, 393 (∼33%) of 1191 TDCJ inmates with CD4 lymphocyte counts !500 cells/mm 3 did not receive HAART in 1998. It is important to consider the following potential explanations for this finding. First, because antiretrovirals may cause major side effects, they are frequently associated with poor adherence, which may result in increased viral resistance. All TDCJ inmates have the right to refuse prescribed therapy, and many of them do. Therefore, in determining when to begin antiretroviral therapy for an asymptomatic patient, physicians are encouraged to consider the patient's willingness to accept therapy, the probability of adherence to the prescribed regimen, and the patient's prognosis in terms of time to onset of AIDS-associated conditions [19] . It is possible, therefore, that in some cases pharmacotherapy was delayed as a result of inmates' history of poor adherence.
Although there is no published information on the rate of antiretroviral adherence rates among prison inmates, research indicates that medication adherence, in general, among prison inmates is substantially poorer than that among the general population [20] . In future investigations, it will be important to determine the percentage of inmates who refuse therapy and their reasons for doing so. The present study, however, did not have access to information on refusals of pharmacotherapy.
In addition, during 1998 1062 (∼45%) of the 2360 patients infected with HIV began both NRTI and HAART regimens. The vast majority of these inmates (828 [78%] of 1062) were switched from NRTI-only regimens to HAART. It is likely that these numbers are at least partly attributable to the widely expanded use of HAART that coincided with the study period. However, because published information on rates of regimen changes in populations infected with HIV during 1998 are scarce, it is difficult to assess the degree to which these findings are representative of nonincarcerated cohorts infected with HIV.
The present study showed that there were no substantial variations in prescribing patterns among TDCJ inmates in relation to sex, race, or age, unlike previous investigations in the general population, which showed substantial differences in HAART use in relation to ethnicity and sex. For example, Shapiro et al. [19] reported that among patients infected with HIV with CD4 lymphocyte counts !500 cells/mm 3 , use of HAART was significantly less among black and female patients, statistically. Research consistently indicates that in the general population, access to and quality of health care vary according to socioeconomic status, race, and sex [21, 22] . The lack of such sociodemographic differentials in the prison setting is likely driven by the fact that, in general, all inmates have equal access to health care.
Conclusion
Given the high prevalence of HIV infection in correctional institution populations, it will be important to continue to monitor the treatment patterns for inmates infected with HIV. Prison inmates who receive suboptimal therapies and who are subsequently released into their home communities may contribute to the development of drug-resistant HIV in the general population. Determination of whether the current patterns of treatment persist in future studies of prison inmates infected with HIV will hold broad clinical and public health relevance.
